Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
Oliff
A
A
allen_oliff@Merck.com
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors* / Q000235:genetics; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002478:Cells, Cultured; D017321:Clinical Trials, Phase I as Topic; D015195:Drug Design; D051231:Farnesyltranstransferase; D011905:Genes, ras / Q000187:drug effects; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D018631:ras Proteins / Q000378:metabolism
D000970:Antineoplastic Agents; D019883:Alkyl and Aryl Transferases; C083291:geranylgeranyltransferase type-I; D051231:Farnesyltranstransferase; D018631:ras Proteins